Profile data is unavailable for this security.
About the company
Genomed SA is a Poland-based company engaged in genetic research. It develops molecular diagnostics based on deoxyribonucleic acid (DNA) sequencing, with a special focus on the Next Generation Sequencing (NGS) method. The Company’s offer includes the analysis of gene mutations responsible for over 150 congenital diseases, such as infertility, predisposition to cancer, cystic fibrosis (CF), Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy and obesity, among others. The Company’s activities are directed toward introducing genomic technology to personalized medicine and creating a clinic offering gene treatments. The Company also provides diverse DNA sequencing, analysis and synthesis services for research and the biotechnological market.
- Revenue in PLN (TTM)22.14m
- Net income in PLN588.66k
- Incorporated2010
- Employees44.00
- LocationGenomed SAul. Ponczowa 12WARSZAWA 02-971PolandPOL
- Phone+48 226446019
- Fax+48 226446025
- Websitehttp://www.genomed.pl/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sygnis SA | 12.42m | -5.52m | 10.60m | 34.00 | -- | 0.2946 | -- | 0.8537 | -0.2396 | -0.2396 | 0.5314 | 1.43 | 0.1752 | 0.6194 | 15.06 | 326,799.50 | -7.89 | -5.73 | -14.77 | -8.31 | 60.82 | 56.42 | -45.06 | -21.11 | 0.4425 | -0.7412 | 0.1151 | -- | -33.38 | 44.26 | -241.23 | -- | 39.45 | -- |
| Stem Cells Spin SA | 223.67k | -353.29k | 10.66m | 1.00 | -- | 1.49 | 14.16 | 47.68 | -0.0086 | -0.0086 | 0.0054 | 0.1734 | 0.0163 | 0.0739 | 4.38 | 223,670.00 | -2.58 | -1.14 | -4.18 | -1.93 | 80.24 | 94.37 | -157.95 | -45.36 | 0.0118 | -225.54 | 0.0074 | -- | 68.84 | -4.37 | -680.05 | -- | -52.67 | -- |
| Braster SA | 284.00k | -4.30m | 18.03m | 10.00 | -- | -- | -- | 63.47 | -0.1494 | -0.1494 | 0.0098 | -0.1717 | 0.0135 | 0.0038 | 2.70 | 28,400.00 | -20.43 | -29.93 | -147.09 | -72.54 | 93.66 | 79.59 | -1,513.38 | -1,124.89 | 0.2905 | -2.66 | 1.77 | -- | -88.96 | -18.11 | 28.68 | -- | -- | -- |
| Hyenergy SA | 462.00k | -6.12m | 23.25m | 27.00 | -- | 8.27 | -- | 50.33 | -1.06 | -1.06 | 0.0776 | 0.4535 | 0.0625 | 0.9737 | 1.39 | -- | -82.83 | 1.90 | -115.27 | 2.58 | -44.16 | 76.43 | -1,325.33 | 2.66 | 1.20 | -1.00 | 0.0106 | -- | -93.14 | -16.73 | -2,069.21 | -- | -- | -- |
| Medicofarma Biotech SA | 1.37m | -2.73m | 26.17m | -- | -- | 3.01 | -- | 19.12 | -0.0402 | -0.0402 | 0.0201 | 0.128 | 0.0895 | 4.57 | 4.74 | -- | -17.87 | -15.05 | -23.82 | -18.17 | 81.92 | 29.92 | -199.65 | -42.86 | 0.8394 | -18.90 | 0.00 | -- | -82.34 | -31.48 | -116.39 | -- | -- | -- |
| GENOMED SA | 22.14m | 588.66k | 34.62m | 44.00 | 58.81 | 3.73 | 28.99 | 1.56 | 0.4455 | 0.4455 | 16.75 | 7.02 | 2.17 | 5.85 | 14.12 | 503,111.40 | 5.77 | 7.77 | 6.39 | 9.19 | 44.00 | 38.53 | 2.66 | 3.87 | 4.64 | 30,446.00 | 0.00 | -- | 9.88 | 3.88 | 174.07 | -8.94 | -32.19 | -- |
| Read Gene SA | 11.63m | -1.00m | 56.83m | 11.00 | -- | 30.45 | -- | 4.89 | -0.1084 | -0.1084 | 1.16 | 0.1583 | 0.9731 | 51.32 | 18.69 | -- | -8.40 | -1.06 | -8.56 | -1.31 | 92.67 | 88.41 | -8.63 | -2.42 | 23.52 | -2.46 | 0.00 | -- | 40.14 | 16.00 | -731.53 | -- | -- | -- |
| Pure Biologics SA | 68.00k | -23.01m | 70.84m | 11.00 | -- | -- | -- | 1,041.79 | -7.09 | -8.27 | 0.0211 | -1.82 | 0.0016 | -- | 0.469 | 1,333.33 | -53.52 | -65.91 | -85.74 | -109.50 | -1,457.35 | 6.97 | -33,838.23 | -487.38 | -- | -7.36 | -- | -- | -85.65 | -60.22 | -39.41 | -- | 1.65 | -- |
| Sds Optic SA | 370.00 | -8.98m | 78.29m | -- | -- | -- | -- | 211,591.80 | -1.52 | -1.52 | 0.00006 | -0.0545 | 0.00003 | 65.75 | 0.0006 | -- | -74.69 | -- | -86.32 | -- | -371,002.80 | -- | -2,452,795.00 | -- | 9.61 | -47.49 | -- | -- | -99.61 | -- | -85.09 | -- | -- | -- |
| Nanogroup SA | 1.02k | -7.12m | 87.39m | -- | -- | 9.38 | -- | 85,681.36 | -0.3541 | -0.3541 | 0.00005 | 0.3253 | 0.00007 | 7.84 | 0.0141 | -- | -45.22 | -23.18 | -51.42 | -26.06 | -99,397.06 | -278.03 | -692,468.60 | -1,567.57 | 2.75 | -858.81 | 0.00 | -- | -98.55 | -55.07 | -840.84 | -- | -8.99 | -- |
| Genomtec SA | 2.00k | -11.00m | 96.35m | -- | -- | 8.20 | -- | 48,173.49 | -0.8971 | -0.8971 | 0.0002 | 0.9582 | 0.00009 | 62.24 | 0.0011 | -- | -47.25 | -- | -60.10 | -- | -115,050.00 | -- | -549,850.00 | -- | 2.06 | -88.39 | 0.1442 | -- | -97.50 | -- | 24.44 | -- | -- | -- |
| Urteste SA | 0.00 | -4.28m | 125.18m | -- | -- | 4.84 | -- | -- | -3.15 | -3.15 | 0.00 | 18.34 | 0.00 | 11.94 | -- | -- | -14.28 | -- | -14.78 | -- | -- | -- | -- | -- | 17.80 | -- | 0.026 | -- | -100.00 | -- | -37.59 | -- | -- | -- |
| Molecure SA | 712.18k | -27.63m | 166.51m | 105.00 | -- | 2.08 | -- | 233.80 | -1.64 | -1.64 | 0.0423 | 4.76 | 0.0054 | -- | 1.06 | 6,416.04 | -21.00 | 2.64 | -21.93 | 2.76 | -272.51 | 97.54 | -3,879.55 | 12.84 | -- | -- | 0.0649 | -- | -18.85 | 237.24 | -19.67 | -- | -24.82 | -- |
Data as of Nov 08 2024. Currency figures normalised to Genomed SA's reporting currency: Polish New Zloty PLN
